Kemicetine

Chloramphenicol sodium succinate, the active ingredient in Kemicetine, is an amphenicol antibiotic presented as an injection for intramuscular and intravenous use. It treats severe bacterial infections such as meningitis, typhoid fever and rickettsial diseases in hospitalized patients.

GNH USA supplies Kemicetine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable cold‑chain logistics for injectable medicines. Clients benefit from consistent batch release, regulatory documentation, and on‑time delivery across multiple continents.

Chloramphenicol sodium succinate is used to treat serious bacterial infections by targeting susceptible organisms within the amphenicol class. - Severe bacterial infections: Provides systemic antibacterial activity for life‑threatening infections. - Meningitis: Achieves rapid bacterial clearance in cerebrospinal fluid to reduce morbidity. - Typhoid fever: Eradicates Salmonella Typhi organisms, aiding recovery in acute systemic illness. - Rickettsial infections: Controls intracellular rickettsiae, improving clinical outcomes in spotted fever and related diseases.

Adverse reactions to chloramphenicol sodium succinate vary in frequency and severity. Common Side Effects: - Nausea: mild gastrointestinal upset. - Rash: skin erythema or itching. - Bone marrow suppression (dose‑related): mild reduction in blood cell counts. Serious or Rare Side Effects: - Aplastic anemia: irreversible bone marrow failure. - Gray syndrome: fatal metabolic acidosis in neonates. - Hepatic toxicity: elevated liver enzymes or jaundice.

Key safety considerations for chloramphenicol sodium succinate include patient monitoring and handling precautions. - Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic dysfunction: assess liver enzymes before and during treatment. - Neonates and infants: avoid use due to risk of Gray syndrome. - Pregnancy: prescribe only when benefit outweighs potential risk. - Blood monitoring: perform regular complete blood counts to detect marrow suppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Chloramphenicol sodium succinate can interact with other medicines, affecting efficacy or safety. Major Interactions (Avoid): - Concurrent bone marrow suppressants: increased risk of severe aplastic anemia. - Alcohol: may exacerbate hepatic toxicity. Moderate Interactions (Monitor Closely): - NSAIDs: potential additive renal toxicity. - Loop diuretics: may alter renal clearance of chloramphenicol. - Anticoagulants: possible enhancement of bleeding tendency.